In addition, we also showed that recombinant human MG53 (rhMG53) could ameliorate pathology of muscular dystrophy mice when it was administrated through intravenous injection [32], suggesting a potential application of rhMG53 in the treatment of diseases with compromised membrane repair, such as cardiac diseases and muscular dystrophy. This evidence concerns the gene TRIM72 and muscular dystrophy.